Rx Pricing/Marketing Defense Based On "Industry Standard" Losing Viability
Executive Summary
Drug manufacturers' claim that their pricing and marketing practices are in line with "industry standards" is not a viable defense, speakers at the Health Care Compliance Association and Food & Drug Law Institute compliance symposium said.